Table 1.

Baseline Patient Demographic and Clinicopathological Characteristics

Variable	Total (n = 164)	Short-Term Treatment Duration (n = 54)	Intermediate Treatment Duration (n = 55)	Long-Term Treatment Duration (n = 55)	P
Follow-Up, Median (Range), years	5.8 (0.7- 22.1)	4.1 (1.0-16.0)	5.1 (0.7-16.7)	7.0 (2.1-22.1)	.001
Age, Median (Range), years	46.6 (22.0- 83.3)	48.6 (22.0-70.0)	45.8 (29.4-75.3)	47.0 (25.1-83.3)	.723
Age Category, n (%)					.919
<50 years	100 (61.0)	32 (59.3)	35 (63.6)	33 (60.0)
≥50 years	64 (39.0)	22 (40.7)	20 (36.4)	22 (40.0)
Race/Ethnicity, n (%)					.691
White	142 (86.6)	49 (90.7)	46 (83.6)	47 (85.5)
Nonwhite	17 (10.4)	4 (7.4)	6 (10.9)	7 (12.7)
Unknown	5 (3.0)	1 (1.9)	3 (5.5)	1 (1.8)
T Stage, n (%)					.127
T1	60 (36.6)	15 (27.8)	21 (38.2)	24 (43.6)
T2	52 (31.7)	22 (40.7)	13 (23.6)	17 (30.9)
T3	8 (4.9)	2 (3.7)	3 (5.5)	3 (5.5)
T4	22 (13.4)	9 (16.7)	11 (20.0)	2 (3.6)
Unknown	22 (13.4)	6 (11.1)	7 (12.3)	9 (16.4)
Nodal Status, n (%)					.596
Positive	102 (62.2)	35 (64.8)	32 (58.2)	35 (63.6)
Negative	45 (27.4)	15 (27.8)	18 (32.7)	12 (21.8)
Unknown	17 (10.4)	4 (7.4)	5 (9.1)	8 (14.6)
AJCC Stage, n (%)					.241
I	34 (20.7)	8 (14.8)	15 (27.3)	11 (20.0)
II	50 (30.5)	21 (38.9)	11 (20.0)	18 (32.7)
III	40 (24.4)	13 (24.1)	17 (30.9)	10 (18.2)
IV	40 (24.4)	12 (22.2)	12 (21.8)	16 (29.1)
HR, n (%)					.136
Positive	92 (56.1)	25 (46.3)	31 (56.4)	36 (65.5)
Negative	72 (43.9)	29 (53.7)	24 (43.6)	19 (34.6)
Histologic Grade, n (%)					.515
Low/intermediate	45 (27.4)	18 (33.3)	12 (21.8)	15 (27.3)
High	102 (62.2)	32 (59.3)	38 (69.1)	32 (58.2)
Unknown	17 (10.4)	4 (7.4)	5 (9.1)	8 (14.6)
Histology, n (%)					.160
Invasive ductal	130 (79.3)	42 (77.8)	44 (80.0)	44 (80.0)
Invasive lobular component	22 (13.4)	11 (20.4)	5 (9.1)	6 (10.9)
Other/unknown	12 (7.3)	1 (1.9)	6 (10.9)	5 (9.1)

Abbreviations: AJCC = American Joint Committee on Cancer Staging; HR = hormone receptor.